Journal
METABOLOMICS
Volume 17, Issue 2, Pages -Publisher
SPRINGER
DOI: 10.1007/s11306-020-01767-y
Keywords
Chronic hepatitis B; Liver fibrosis; FibroScan; Biomarker; Metabolomics; NMR
Categories
Funding
- Innovation Fund Denmark
- Obel Family Foundation
- SparNord Foundation
- Carlsberg Foundation
Ask authors/readers for more resources
This study aims to identify the metabolic signature of different stages in chronic hepatitis B (CHB) patients through metabolome analysis and develop a more accurate diagnosis method. Results show that metabolomics approach can successfully discover the progression of the disease and differentiate metabolomes at different treatment stages.
IntroductionChronic hepatitis B (CHB) affects 257 million individuals worldwide with an annual estimated mortality rate of 880,000 individuals. Accurate diagnosis of the stage of disease is difficult, and there is considerable uncertainty concerning the optimal point in time, when treatment should be started.ObjectivesBy analyzing and comparing the metabolomes of patients at different stages of CHB and comparing them to healthy individuals, we want to determine the metabolic signature of disease progression and develop a more accurate metabolome-based method for diagnosis of disease progression ultimately giving a better basis for treatment decisions.MethodsIn this study, we used the combination of transient elastography and serum metabolomics of 307 serum samples from a group of 90 patients with CHB before and under treatment (with a follow-up time up to 10 years) at different progression stages over the clinical phases and 43 healthy controls..ResultsOur data show that the metabolomics approach can successfully discover CHB changing from the immune tolerance to the immune clearance phase and show distinctive metabolomes from different medical treatment stages. Perturbations in ammonia detoxification, glutamine and glutamate metabolism, methionine metabolism, dysregulation of branched-chain amino acids, and the tricarboxylic acid (TCA) cycle are the main factors involved in the progression of the disease. Fluctuations increasing in aspartate, glutamate, glutamine, methionine and 13 other metabolites are fingerprints of progression.ConclusionsThe metabolomics approach may expand the diagnostic armamentarium for patients with CHB. This method can provide a more detailed decision basis for starting medical treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available